SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 720.46 |
Enterprise Value ($M) | 675.25 |
Book Value ($M) | 419.46 |
Book Value / Share | 1.24 |
Price / Book | 1.71 |
NCAV ($M) | 402.54 |
NCAV / Share | 1.18 |
Price / NCAV | 1.79 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -1.41 |
Return on Assets (ROA) | -0.99 |
Return on Equity (ROE) | -1.02 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 9.01 |
Current Ratio | 9.01 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 475.57 |
Assets | 492.49 |
Liabilities | 73.03 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 7.87 |
Operating Income | -167.56 |
Net Income | -567.94 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -130.41 |
Cash from Investing | 122.70 |
Cash from Financing | 0.33 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Fmr Llc | 15.00 | 11.73 | |
13G/A | BlackRock, Inc. | 4.90 | 27.62 | |
13D/A | Omega Fund V, L.P. | 3.90 | -13.27 | |
13D | Decheng Capital China Life Sciences USD Fund III, L.P. | 8.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
1,574,769 | 4,310,325 | 36.53 | |
818,855 | 5,768,675 | 14.19 | |
1,138,844 | 7,038,918 | 16.18 | |
894,721 | 3,948,542 | 22.66 | |
(click for more detail) |
Similar Companies | |
---|---|
JNJ – Johnson & Johnson | LLY – Eli Lilly and Company |
MRK – Merck & Co., Inc. | OGN – Organon & Co. |
PBH – Prestige Consumer Healthcare Inc. |
Financial data and stock pages provided by
Fintel.io